Mumps virus

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Rubin, Steven A ^a   Sauder, Christian J ^a   Carbone, Kathryn M ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974678495     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (438)

1. Aase JM, Noren GR, Reddy DV, et al. Mumps-virus infection in pregnant women and the immunologic response of their offspring. N Engl J Med 1972;286:1379-1382.
2. Abdelbaky AM, Channappa DB, Islam S. Unilateral epididymo-orchitis: a rare complication of MMR vaccine. Ann R Coll Surg Engl 2008;90:336-337.
3. Afzal MA, Buchanan J, Dias JA, et al. RT-PCR based diagnosis and molecular characterisation of mumps viruses derived from clinical specimens collected during the 1996 mumps outbreak in Portugal. J Med Virol 1997;52:349-353.
4. Afzal MA, Dussupt V, Minor PD, et al. Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations. J Virol Methods 2005;126:149-156.
5. Afzal MA, Elliott GD, Rima BK, et al. Virus and host cell-dependent variation in transcription of the mumps virus genome. J Gen Virol 1990;71(Pt 3):615-619.
6. Afzal MA, Pickford AR, Forsey T, et al. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J GenVirol 1993;74(Pt 5):917-920.
7. Afzal MA, Yates PJ, Minor PD. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J Infect Dis 1998;177:265-266.
8. Amexis G, Rubin S, Chatterjee N, et al. Identification of a new genotype H wild-type mumps virus strain and its molecular relatedness to other virulent and attenuated strains. J Med Virol 2003;70:284-286.
9. Amexis G, Rubin SA, Chizhikov V, et al. Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality control. Virology 2002;300:171-179.
10. Anderson RM, Crombie JA, Grenfell BT. The epidemiology of mumps in the UK: a preliminary study of virus transmission, herd immunity and the potential impact of immunization. Epidemiol Infect 1987;99:65-84.
11. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature 1985;318:323-329.
12. Andrejeva J, Childs KS, Young DF, et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A 2004;101:17264-17269.
13. Arday DR, Kanjarpane DD, Kelley PW. Mumps in the US Army 1980-86: should recruits be immunized? Am J Public Health 1989;79:471-474.
14. Arita M, Ueno Y, Masuyama Y. Complete heart block in mumps myocarditis. Br Heart J 1981;46:342-344.
15. Asatryan A, Pool V, Chen RT, et al. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990-2003. Vaccine 2008;26:1166-1172.
16. Association for the Study of Infectious Disease. A retrospective survey of the complications of mumps. J R Coll Gen Pract 1974;24:552-556.
17. Atrasheuskaya AV, Neverov AA, Rubin S, et al. Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine 2006;24:1530-1536.
18. Aygun AD, Kabakus N, Celik I, et al. Long-term neurological outcome of acute encephalitis. J Trop Pediatr 2001;47:243-247.
19. Azimi PH, Shaban S, Hilty MD, et al. Mumps meningoencephalitis. Prolonged abnormality of cerebrospinal fluid. JAMA 1975;234:1161-1162.
20. Bang HO, Bang J. Involvement of the central nervous system in mumps. Acta Med Scand 1943;113:487-505.
21. Bangor-Jones RD, Dowse GK, Giele CM, et al. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust 2009;191:398-401.
22. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009;27:6186-6195.
23. Bashe WJ Jr, Gotlieb T, Henle G, et al. Studies on the prevention of mumps. VI. The relationship of neutralizing antibodies to the determination of susceptibility and to the evaluation of immunization procedures. J Immunol 1953;71:76-85.
24. Bautista-Lopez N, Ward BJ, Mills E, et al. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000;18:1393-1401.
25. Beard CM, Benson RC, Kelalis PP, et al. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clin Proc 1977;52:3-7.
26. Bertotto A, Spinozzi F, Gerli R, et al. Gamma delta T lymphocytes in mumps meningitis patients. Acta Paediatr 1995;84:1268-1270.
27. Bitnun S, Rakover Y, Rosen G. Acute bilateral total deafness complicating mumps. J Laryngol Otol 1986;100:943-945.
28. Bitsko RH, Cortese MM, Dayan GH, et al. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. J Clin Microbiol 2008;46:1101-1103.
29. Bjorvatn B. Mumps virus recovered from testicles by fine-needle aspiration biopsy in cases of mumps orchitis. Scand J Infect Dis 1973;5:3-5.
30. Bjorvatn B, Wolontis S. Mumps meningoencephalitis in Stockholm, November 1964-July 1971. I. Analysis of a hospitalized study group. Questions of selection and representativity. Scand J Infect Dis 1973;5:253-260.
31. Black FL, Hierholzer WJ, Pinheiro F, et al. Evidence for persistence of infectious agents in isolated human populations. Am J Epidemiol 1974;100:230-250.
32. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one-to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997;16:500-503.
33. Boddicker JD, Rota PA, Kreman T, et al. Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens. J Clin Microbiol 2007;45:2902-2908.
34. Bonnet MC, Dutta A, Weinberger C, et al. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006;24:7037-7045.
35. Boriskin YS, Booth JC, Yamada A. Sequence variation within the carboxyl terminus of the nucleoprotein gene of mumps virus strains. Clin Diagn Virol 1994;2:79-85.
36. Boulianne N, De Serres G, Ratnam S, et al. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 1995;13:1611-1616.
37. Bousse TL, Taylor G, Krishnamurthy S, et al. Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein. J Virol 2004;78:13351-13355.
38. Boxall N, Kubinyiova M, Prikazsky V, et al. An increase in the number of mumps cases in the Czech Republic, 2005-2006. Eurosurveillance 2008;13.
39. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994;169:77-82.
40. Broliden K, Abreu ER, Arneborn M, et al. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998;16:323-327.
41. Brown GC, Baublis JV, O'Leary TP. Development and duration of mumps fluorescent antibodies in various immunoglobulin fractions of human serum. J Immunol 1970;104:86-94.
42. Brown JW, Kirkland HB, Hein GE. Central nervous system involvement during mumps. Am J Med Sci 1948;215:434-441.
43. Brown NJ, Richmond SJ. Fatal mumps myocarditis in an 8-month-old child. Br Med J 1980;281:356-357.
44. Brunell PA, Brickman A, O'Hare D, et al. Ineffectiveness of isolation of patients as a method of preventing the spread of mumps. Failure of the mumps skin-test antigen to predict immune status. N Engl J Med 1968;279:1357-1361.
45. Brunell PA, Brickman A, Steinberg S. Evaluation of a live attenuated mumps vaccine (Jeryl Lynn). With observations on the optimal time for testing serologic response. Am J Dis Child 1969;118:435-440.
46. Bruyn HB, Sexton HM, Brainerd HD. Mumps meningoencephalitis. A clinical review of 119 cases with one death. Calif Med 1957;86:153-160.
47. Buxton J, Craig C, Daly P, et al. An outbreak of mumps among young adults in Vancouver, British Columbia, associated with 'rave' parties. Can J Public Health 1999;90:160-163.
48. Castilla J, Garcia CM, Arriazu M, et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine 2009;27:2089-2093.
49. Cebulla CM, Miller DM, Sedmak DD. Viral inhibition of interferon signal transduction. Intervirology 1999;42:325-330.
50. Centers for Diease Control and Prevention. Status report on the Childhood Immunization Initiative: national, state, and urban area vaccination coverage levels among children aged 19-35 months-United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:657-664.
51. Centers for Disease Control and Prevention. Mumps surveillance report. MMWR Morb Mortal Wkly Rep 1972;21:1-12.
52. Centers for Disease Control and Prevention. Current Trends Mumps-United States, 1984-1985. MMWR Morb Mortal Wkly Rep 1986;35:216-219.
53. Centers for Disease Control and Prevention. Measles prevention. MMWR Morb Mortal Wkly Rep 1989;38(Suppl 9):1-18.
54. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1996. MMWR Morb Mortal Wkly Rep 1996;45:1-88.
55. Centers for Disease Control and Prevention. Measles, mumps, and rubella-Vaccine use and strategies for the elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47:1-48.
56. Centers for Disease Control and Prevention. Summary of notifiable diseases, 2003. MMWR Morb Mortal Wkly Rep 2005;52:17-72.
57. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19-35 months-United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:988-993.
58. Centers for Disease Control and Prevention. Summary of Notifiable Diseases-United States, 2007. MMWR Morb Mortal Wkly Rep 2009;56:1-94.
59. Centers for Disease Control and Prevention. Summary of Notifiable Diseases-United States, 2008. MMWR Morb Mortal Wkly Rep 2009;57:1-94.
60. Centers for Disease Control and Prevention. 2010. Guide to vaccine contraindications and precautions. Available at: http://www.cdc.gov/vaccines/recs/vac-admin/downloads/contraindications-guide-508.pdf.
61. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1018-1023.
62. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1171-1177.
63. Centers for Disease Control and Prevention. Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 2010;59:1658-1671.
64. Centers for Disease Control and Prevention. Update: mumps outbreak-New York and New Jersey, June 2009-January 2010. MMWR Morb Mortal Wkly Rep 2010;59:125-129.
65. Cheek JE, Baron R, Atlas H, et al. Mumps outbreak in a highly vaccinated school population. Arch Pediatr Adolesc Med 1995;149:774-778.
66. Chiba Y, Dzierba JL, Morag A, et al. Cell-mediated immune response to mumps virus infection in man. J Immunol 1976;116:12-15.
67. Chiba Y, Horino K, Umetsu M, et al. Virus excretion and antibody response in saliva in natural mumps. Tohoku J Exp Med 1973;111:229-238.
68. Chiba Y, Nakao T. Mumps virus neutralizing antibody in saliva following natural infection. Tohoku J Exp Med 1972;106:75-81.
69. Chiba Y, Tsutsumi H, Nakao T, et al. Human leukocyte antigen-linked genetic controls for T-cell mediated cytotoxicity response to mumps virus in humans. Infect Immun 1982;35:600-604.
70. Chu TH, Cheever FS, Coons AH, et al. Distribution of mumps virus in the experimentally infected monkey. Proc Soc Exp Biol Med 1951;76:571-574.
71. Cinalli G, Spennato P, Ruggiero C, et al. Aqueductal stenosis 9 years after mumps meningoencephalitis: treatment by endoscopic third ventriculostomy. Childs Nerv Syst 2004;20:61-64.
72. Cizman M, Mozetic M, Radescek-Rakar R, et al. Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J 1989;8:302-308.
73. Clifford V, Wadsley J, Jenner B, et al. Mumps vaccine associated orchitis: Evidence supporting a potential immune-mediated mechanism. Vaccine 2010;28:2671-2673.
74. Cochi SL, Preblud SR, Orenstein WA. Perspectives on the relative resurgence of mumps in the United States. Am J Dis Child 1988;142:499-507.
75. Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007;13:12-17.
76. Collins SD. Age incidence of the common communicable diseases of children. Pub Health Rep 1929;44:763-826.
77. Connaris H, Takimoto T, Russell R, et al. Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion. J Virol 2002;76:1816-1824.
78. Connolly SA, Leser GP, Jardetzky TS, et al. Bimolecular complementation of paramyxovirus fusion and hemagglutinin-neuraminidase proteins enhances fusion: implications for the mechanism of fusion triggering. J Virol 2009;83:10857-10868.
79. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol 1975;101:532-551.
80. Cortese MM, Barskey AE, Tegtmeier GE, et al. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis 2011;204(9):1413-1422.
81. Cortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 2008;46:1172-1180.
82. Cox R, Green TJ, Qiu S, et al. Characterization of a mumps virus nucleocapsidlike particle. J Virol 2009;83:11402-11406.
83. Craighead JE. The role of viruses in the pathogenesis of pancreatic disease and diabetes mellitus. Prog Med Virol 1975;19:161-214.
84. Crennell S, Takimoto T, Portner A, et al. Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol 2000;7:1068-1074.
85. Crovari P, Gabutti G, Giammanco G, et al. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines. Vaccine 2000;18:2796-2803.
86. Cunningham C, Faherty C, Cormican M, et al. Importance of clinical features in diagnosis of mumps during a community outbreak. Ir Med J 2006;99:171-173.
87. Curran J, Boeck R, Lin-Marq N, et al. Paramyxovirus phosphoproteins form homotrimers as determined by an epitope dilution assay, via predicted coiled coils. Virology 1995;214:139-149.
88. Curran J, Homann H, Buchholz C, et al. The hypervariable C-terminal tail of the Sendai paramyxovirus nucleocapsid protein is required for template function but not for RNA encapsidation. J Virol 1993;67:4358-4364.
89. Curran JA, Quinn JP, Hoey EM, et al. cDNA cloning of the nucleocapsid and nucleocapsid-associated protein genes of mumps virus. J Gen Virol 1985;66(Pt 5):977-985.
90. Cusi MG, Bianchi S, Valassina M, et al. Rapid detection and typing of circulating mumps virus by reverse transcription/polymerase chain reaction. Res Virol 1996;147:227-232.
91. Cusi MG, Fischer S, Sedlmeier R, et al. Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. Virus Res 2001;74:133-137.
92. Dacou-Voutetakis C, Constantinidis M, Moschos A, et al. Diabetes mellitus following mumps. Insulin reserve. Am J Dis Child 1974;127:890-891.
93. Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008;197:1662-1668.
94. Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008;197:950-956.
95. Davidkin I, Kontio M, Paunio M, et al. MMR vaccination and disease elimination: the Finnish experience. Expert Rev Vaccines 2010;9:1045-1053.
96. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 1995;13:1617-1622.
97. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med 2008;358:1580-1589.
98. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008;47:1458-1467.
99. de Boer AW, de Vaan GA. Mild course of mumps in patients with acute lymphoblastic leukaemia. Eur J Pediatr 1989;148:618-619.
100. Deibel R, Schryver GD. Viral antibody in the cerebrospinal fluid of patients with acute central nervous system infections. J Clin Microbiol 1976;3:397-401.
101. Donald PR, Burger PJ, Becker WB. Mumps meningo-encephalitis. S Afr Med J 1987;71:283-285.
102. Donohue WL, Playfair FD, Whitaker L. Mumps encephalitis: pathology and pathogenesis. J Pediatr 1955;47:395-412.
103. Ehrengut W, Georges AM, Andre FE. The reactogenicity and immunogenicity of the Urabe Am 9 live mumps vaccine and persistence of vaccine induced antibodies in healthy young children. J Biol Stand 1983;11:105-113.
104. Elango N, Kovamees J, Varsanyi TM, et al. mRNA sequence and deduced amino acid sequence of the mumps virus small hydrophobic protein gene. J Virol 1989;63:1413-1415.
105. Elango N, Varsanyi TM, Kovamees J, et al. Molecular cloning and characterization of six genes, determination of gene order and intergenic sequences and leader sequence of mumps virus. J GenVirol 1988;69(Pt 11):2893-2900.
106. Elliott GD, Afzal MA, Martin SJ, et al. Nucleotide sequence of the matrix, fusion and putative SH protein genes of mumps virus and their deduced amino acid sequences. Virus Res 1989;12:61-75.
107. Elliott GD, Yeo RP, Afzal MA, et al. Strain-variable editing during transcription of the P gene of mumps virus may lead to the generation of non-structural proteins NS1 (V) and NS2. J GenVirol 1990;71:1555-1560.
108. Enders JF. Techniques of laboratory diagnosis, tests for susceptibility, and experiments on specific prophylaxis. J Pediatr 1946;29:129-142.
109. Ennis FA. Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies. J Infect Dis 1969;119:654-657.
110. Ennis FA, Douglas RD, Hopps HE, et al. Clinical studies with virulent and attenuated mumps viruses. Am J Epidemiol 1969;89:176-183.
111. Everberg G. Deafness following mumps. Acta Otolaryngol 1957;48:397-403.
112. Falk WA, Buchan K, Dow M, et al. The epidemiology of mumps in southern Alberta 1980-1982. Am J Epidemiol 1989;130:736-749.
113. Feldman G, Zer M. Infantile acute pancreatitis after mumps vaccination simulating an acute abdomen. Pediatr Surg Int 2000;16:488-489.
114. Feldstein JD, Johnson FR, Kallick CA, et al. Acute hemorrhagic pancreatitis and pseudocyst due to mumps. Ann Surg 1974;180:85-88.
115. Fescharek R, Quast U, Maass G, et al. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects. Vaccine 1990;8:446-456.
116. Fleischer B, Kreth HW. Clonal analysis of HLA-restricted virus-specific cytotoxic T lymphocytes from cerebrospinal fluid in mumps meningitis. J Immunol 1983;130:2187-2190.
117. Forsberg P, Fryden A, Link H, et al. Viral IgM and IgG antibody synthesis within the central nervous system in mumps meningitis. Acta Neurol Scand 1986;73:372-380.
118. Forsey T, Mawn JA, Yates PJ, et al. Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing. J GenVirol 1990;71(Pt 4):987-990.
119. Frankova V, Sixtova E. Specific IgM antibodies in the saliva of mumps patients. Acta Virol 1987;31:357-364.
120. Friedman MG. Salivary IgA antibodies to mumps virus during and after mumps. J Infect Dis 1981;143:617.
121. Fryden A, Link H, Moller E. Demonstration of CSF lymphocytes sensitized against mumps virus antigens in mumps meningitis. Acta Neurol Scand 1978;57:396-404.
122. Fu C, Liang J, Wang M. Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Clin Vaccine Immunol 2008;15:1425-1428.
123. Fuentes SM, Sun D, Schmitt AP, et al. Phosphorylation of paramyxovirus phosphoprotein and its role in viral gene expression. Future Microbiol 2010;5:9-13.
124. Fuller IC. Mumps and its complications: an example of the utilization of disease indices. J R Coll Gen Pract 1968;16:494-496.
125. Galazka A, Kraigher A, Robertson SE. [Wide spread inflammation of the parotid glands (mumps): underestimated disease. I. Epidemiology of the mumps and its medical meaning in Poland]. Przegl Epidemiol 1998;52:389-400.
126. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ 1999;77:3-14.
127. Gamble DR. Relation of antecedent illness to development of diabetes in children. Br Med J 1980;281:99-101.
128. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999;162:5569-5575.
129. Garcia AG, Pereira JM, Vidigal N, et al. Intrauterine infection with mumps virus. Obstet Gynecol 1980;56:756-759.
130. Gellis SS, McGuiness AC, Peters M. A study of the prevention of mumps orchitis by gammaglobulin. Am J Med Sci 1945;210:661-664.
131. Ghosh JK, Ovadia M, Shai Y. A leucine zipper motif in the ectodomain of Sendai virus fusion protein assembles in solution and in membranes and specifically binds biologically-active peptides and the virus. Biochemistry 1997;36:15451-15462.
132. Gibbs FA, Gibbs EL, Spies HW, et al. Common types of childhood encephalitis: electroencephalographic and clinical relationships. Arch Neurol 1964;10:1-11.
133. Glick C, Feldman S, Norris MR, et al. Measles, mumps, and rubella serology in premature infants weighing less than 1,000 grams. South Med J 1998;91:159-160.
134. Gluck R, Hoskins JM, Wegmann A, et al. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells. Dev Biol Stand 1986;65:29-35.
135. Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet 1999;354:1355-1356.
136. Goldacre MJ, Wotton CJ, Yeates D, et al. Hospital admission for selected single virus infections prior to diabetes mellitus. Diabetes Res Clin Pract 2005;69:256-261.
137. Gonzalez-Gil J, Zarrabeitia MT, Altuzarra E, et al. Hydrocephalus: a fatal late consequence of mumps encephalitis. J Forensic Sci 2000;45:204-207.
138. Gordon JE, Heeren RH. The epidemiology of mumps. Am J Med Sci 1940;200:338-359.
139. Gordon SC, Lauter CB. Mumps arthritis: a review of the literature. Rev Infect Dis 1984;6:338-344.
140. Gotoh H, Shioda T, Sakai Y, et al. Rescue of Sendai virus from viral ribonucleoprotein-transfected cells by infection with recombinant vaccinia viruses carrying Sendai virus L and P/C genes. Virology 1989;171:434-443.
141. Granata S. Sulla etiologia degli orecchioni da virus filtrable. Med Ital 1908;6:647-649.
142. Gresser I, Enders JF. Cytopathogenicity of mumps virus in cultures of chick embryo and human ammnion cells. Proc Soc Exp Biol Med 1961;107:804-807.
143. Gut JP, Lablache C, Behr S, et al. Symptomatic mumps virus reinfections. J Med Virol 1995;45:17-23.
144. Habel K. Preparation of mumps vaccine and immunization of monkeys against experimental mumps infection. Public Health Rep 1946;61:1655-1664.
145. Habel K. Cultivation of mumps virus in the developing chick embryo and its application to studies of immunity to mumps in man. Public Health Rep 1945;60:201-212.
146. Hall R, Richards H. Hearing loss due to mumps. Arch Dis Child 1987;62:189-191.
147. Hamaguchi M, Yoshida T, Nishikawa K, et al. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology 1983;128:105-117.
148. Hamilton R. An account of a distemper by the common people of England vulgarly called the mumps. Trans R Soc Edinb 1790;2:59-72.
149. Hammer SM, Connolly KJ. Viral aseptic meningtis in the United States: clinical features, viral etiologies, and differential diagnosis. Curr Clin Top Infect Dis 1992;12:1-25.
150. Hanna-Wakim R, Yasukawa LL, Sung P, et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis 2008;197(12):1669-1675.
151. Hariya Y, Yokosawa N, Yonekura N, et al. Mumps virus can suppress the effective augmentation of HPC-induced apoptosis by IFN-gamma through disruption of IFN signaling in U937 cells. Microbiol Immunol 2000;44:537-541.
152. Harrison MS, Sakaguchi T, Schmitt AP. Paramyxovirus assembly and budding: building particles that transmit infections. Int J Biochem Cell Biol 2010;42:1416-1429.
153. Hashimoto H, Fujioka M, Kinumaki H. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J 2009;28:173-175.
154. Hatchette T, Davidson R, Clay S, et al. Laboratory diagnosis of mumps in a partially immunized population: The Nova Scotia experience. Can J Infect Dis Med Microbiol 2009;20:e157-e162.
155. Hayashi K, Ross ME, Notkins AL. Persistence of mumps viral antigens in mouse brain. Jpn J Exp Med 1976;46:197-200.
156. He B, Leser GP, Paterson RG, et al. The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells. Virology 1998;250:30-40.
157. He B, Lin GY, Durbin JE, et al. The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells. J Virol 2001;75:4068-4079.
158. Henle G, Enders JF. Mumps virus. In: Horstfall F, Tamm I, eds. Viral and Rickettsial Infections of Man. Philadelphia: Lippincott; 1965:755-768.
159. Henle G, Henle W, Wendell K, et al. Isolation of mumps virus from human being with induced apparent or inapparent infections. J Exp Med 1948;88:223-232.
160. Hensel M, Gutjahr P, Kamin W, et al. [Meningitis in 154 children of a pediatric clinic in Germany: clinical and epidemiologic aspects]. Klin Padiatr 1992;204:163-170.
161. Herndon RM, Johnson RT, Davis LE, et al. Ependymitis in mumps virus meningitis. Electron microscopical studies of cerebrospinal fluid. Arch Neurol 1974;30:475-479.
162. Herrler G, Compans RW. Synthesis of mumps virus polypeptides in infected Vero cells. Virology 1982;119:430-438.
163. Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187-193.
164. Hilleman MR. Past, present, and future of measles, mumps, and rubella virus vaccines. Pedatrics 1992;90:149-153.
165. Hilleman MR, Weibel RE, Buynak EB, et al. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N Engl J Med 1967;276:252-258.
166. Hirsch A. Handbook of Geographical and Historical Pathology. Volume I: Acute Infective Diseases. London: Sydenham Society; 1883.
167. Hope-Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952;2:549-554.
168. Horne R, Waterson A, Wildy P, et al. The structure and composition of the myxoviruses: I. Electron microscope studies of the structure of myxovirus particles by negative staining techniques. Virology 1960;11:79-98.
169. Hosaka Y, Shimizu K. Lengths of the nucleocapsids of Newcastle disease and mumps viruses. J Mol Biol 1968;35:369-373.
170. Houard S, Varsanyi TM, Milican F, et al. Protection of hamsters against experimental mumps virus (MuV) infection by antibodies raised against the MuV surface glycoproteins expressed from recombinant vaccinia virus vectors. J Gen Virol 1995;76(Pt 2):421-423.
171. Hrynash Y, Nadraga A, Dasho M. Effectiveness of a vaccination program against mumps in Ukraine. Eur J Clin Microbiol Infect Dis 2008;27:1171-1176.
172. Hyatt HW. Complications of mumps. G.P. 1962;25:124-126.
173. Ichiba N, Miyake Y, Sato K, et al. Mumps-induced opsoclonus-myoclonus and ataxia. Pediatr Neurol 1988;4:224-227.
174. Ilonen J. Lymphocyte blast transformation response of seropositive and seronegative subjects to herpes simplex, rubella, mumps and measles virus antigens. Acta Pathol Microbiol Scand [C] 1979;87C:151-157.
175. Ilonen J, Salmi A, Penttinen K, et al. Lymphocyte blast transformation and antibody responses after vaccination with inactivated mumps virus vaccine. Acta Pathol Microbiol Scand [C] 1981;89:303-309.
176. Inou Y, Nakayama T, Yoshida N, et al. Molecular epidemiology of mumps virus in Japan and proposal of two new genotypes. J Med Virol 2004;73:97-104.
177. Ivancic J, Gulija TK, Forcic D, et al. Genetic characterization of L-Zagreb mumps vaccine strain. Virus Res 2005;109:95-105.
178. Ivancic-Jelecki J, Santak M, Forcic D. Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains. Infect Genet Evol 2008;8(5):603-613.
179. Jalal H, Bahadur G, Knowles W, et al. Mumps epididymo-orchitis with prolonged detection of virus in semen and the development of anti-sperm antibodies. J Med Virol 2004;73:147-150.
180. Jaye A, Magnusen AF, Sadiq AD, et al. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J Clin Invest 1998;102:1969-1977.
181. Jaye A, Magnusen AF, Whittle HC. Human leukocyte antigen class I-and class II-restricted cytotoxic T lymphocyte responses to measles antigens in immune adults. J Infect Dis 1998;177:1282-1289.
182. Jensik SC, Silver S. Polypeptides of mumps virus. J Virol 1976;17:363-373.
183. Jin L, Feng Y, Parry R, et al. Real-time PCR and its application to mumps rapid diagnosis. J Med Virol 2007;79:1761-1767.
184. Jin L, Rima B, Brown D, et al. Proposal for genetic characterisation of wild-type mumps strains: Preliminary standardisation of the nomenclature. Arch Virol 2005;150:1903-1909.
185. Johansson B, Tecle T, Orvell C. Proposed criteria for classification of new genotypes of mumps virus. Scand J Infect Dis 2002;34:355-357.
186. Johnson CD, Goodpasture EW. An investigation of the etiology of mumps. J Exp Med 1934;59:1-19.
187. Johnson CD, Goodpasture EW. The etiology of mumps. Am J Hyg 1935;21:46-57.
188. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996;15:687-692.
189. Johnson KP, Johnson RT. Granular ependymitis. Occurrence in myxovirus infected rodents and prevalence in man. Am J Pathol 1972;67:511-526.
190. Johnson RT. Viral Infection of the Nervous System. New York: Raven Press; 1982.
191. Johnson RT, Johnson KP. Hydrocephalus following viral infection: the pathology of aqueductal stenosis developing after experimental mumps virus infection. J Neuropathol Exp Neurol 1968;27:591-606.
192. Johnson RT, Johnson KP, Edmonds CJ. Virus-induced hydrocephalus: development of aqueductal stenosis in hamsters after mumps infection. Science 1967;157:1066-1067.
193. Johnstone JA, Ross CA, Dunn M. Meningitis and encephalitis associated with mumps infection. A 10-year survey. Arch Dis Child 1972;47:647-651.
194. Jokinen S, Osterlund P, Julkunen I, et al. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis 2007;196:861-867.
195. Jones JF, Ray CG, Fulginiti VA. Perinatal mumps infection. J Pediatr 1980;96:912-914.
196. Kaic B, Gjenero-Margan I, Aleraj B, et al. Transmission of the L-Zagreb mumps vaccine virus, Croatia, 2005-2008. Euro Surveill 2008;13(16):18843.
197. Kakakios AM, Burgess MA, Bransby RD, et al. Optimal age for measles and mumps vaccination in Australia. Med J Aust 1990;152:472-474.
198. Kanra G, Isik P, Kara A, et al. Complementary findings in clinical and epidemiologic features of mumps and mumps meningoencephalitis in children without mumps vaccination. Pediatr Int 2004;46:663-668.
199. Kaplan KM, Marder DC, Cochi SL, et al. Mumps in the workplace. Further evidence of the changing epidemiology of a childhood vaccine-preventable disease. JAMA 1988;260:1434-1438.
200. Ki M, Park T, Yi SG, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol 2003;157:158-165.
201. Kilham L. Isolation of mumps virus from the blood of a patient. Proc Soc Exp Biol Med 1948;69:99-100.
202. Kilham L. Mumps meningoencephalitis with and without parotitis. Am J Dis Child 1949;78:324-333.
203. Kilham L. Mumps virus in human milk and in milk of infected monkey. J Am Med Assoc 1951;146:1231-1232.
204. Kilham L, Margolis G. Induction of congenital hydrocephalus in hamsters with attenuated and natural strains of mumps virus. J Infect Dis 1975;132:462-466.
205. Kilham L, Murphy HW. Propagation of mumps virus in suckling mice and in mouse embryo tissue cultures. Proc Soc Exp Biol Med 1952;80:495-498.
206. Kimura M, Kuno-Sakai H, Yamazaki S, et al. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn 1996;38:205-211.
207. Kingston RL, Baase WA, Gay LS. Characterization of nucleocapsid binding by the measles virus and mumps virus phosphoproteins. J Virol 2004;78:8630-8640.
208. Kingston RL, Gay LS, Baase WS, et al. Structure of the nucleocapsid-binding domain from the mumps virus polymerase; an example of protein folding induced by crystallization. J Mol Biol 2008;379:719-731.
209. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child 1982;136:362-364.
210. Koskiniemi M, Donner M, Pettay O. Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand 1983;72:603-609.
211. Kovamees J, Rydbeck R, Orvell C, et al. Hemagglutinin-neuraminidase (HN) amino acid alterations in neutralization escape mutants of Kilham mumps virus. Virus Res 1990;17:119-129.
212. Kozak M. A short leader sequence impairs the fidelity of initiation by eukaryotic ribosomes. Gene Expr 1991;1:111-115.
213. Krause CH, Eastick K, Ogilvie MM. Real-time PCR for mumps diagnosis on clinical specimens-comparison with results of conventional methods of virus detection and nested PCR. J Clin Virol 2006;37:184-189.
214. Krause CH, Molyneaux PJ, Ho-Yen DO, et al. Comparison of mumps-IgM ELISAs in acute infection. J Clin Virol 2007;38(2):153-156.
215. Kreth HW, Kress L, Kress HG, et al. Demonstration of primary cytotoxic T cells in venous blood and cerebrospinal fluid of children with mumps meningitis. J Immunol 1982;128:2411-2415.
216. Kubota T, Yokosawa N, Yokota S, et al. C terminal CYS-RICH region of mumps virus structural V protein correlates with block of interferon alpha and gamma signal transduction pathway through decrease of STAT 1-alpha. Biochem Biophys Res Commun 2001;283:255-259.
217. Kuczyk MA, Denil J, Thon WF, et al. Orchitis following mumps vaccination in an adult. Urol Int 1994;53:179-180.
218. Kuhlman JC. Mumps outbreak aboard the USS Reuben James. Mil Med 1994;159:255-257.
219. Kulkarni-Kale U, Ojha J, Manjari GS, et al. Mapping antigenic diversity and strain specificity of mumps virus: a bioinformatics approach. Virology 2007;359:436-446.
220. Kunkel U, Schreier E, Siegl G, et al. Molecular characterization of mumps virus strains circulating during an epidemic in eastern Switzerland 1992/93. Arch Virol 1994;136:433-438.
221. Kurtz JB, Tomlinson AH, Pearson J. Mumps virus isolated from a fetus. Br Med J (Clin Res Ed) 1982;284:471.
222. Lacour M, Maherzi M, Vienny H, et al. Thrombocytopenia in a case of neonatal mumps infection: evidence for further clinical presentations. Eur J Pediatr 1993;152:739-741.
223. Larke RP. Interferon in the cerebrospinal fluid of children with central nervous system disorders. Can Med Assoc J 1967;96:21-32.
224. Laurence D, McGavin D. The complications of mumps. Br Med J 1948;1:94-97.
225. Lavi S, Zimmerman B, Koren G, et al. Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. JAMA 1990;263:269-271.
226. Lawrence MC, Borg NA, Streltsov VA, et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J Mol Biol 2004;335:1343-1357.
227. LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009;199:552-560.
228. Leboreiro-Fernandez A, Moura-Ribeiro M, Leboreiro I, et al. Mumps meningoencephalitis, an epidemiological approach. Arq Neuropsiquiatr 1997;55:12-15.
229. Lee JY, Kim YY, Shin GC, et al. Molecular characterization of two genotypes of mumps virus circulated in Korea during 1998-2001. Virus Res 2003;97:111-116.
230. Levenbook IS, Nikolayeva MA, Chigirinsky AE, et al. On the morphological evaluation of neurovirulence safety of attenuated mumps virus strains in monkeys. J Biol Stand 1979;7:9-19.
231. Levens J, Enders JF. The hemagglutinative properties of amniotic fluid from embryonated eggs infected with mumps virus. Science 1945;102:117-120.
232. Levine MI. A sponsored epidemic of mumps in a private school. Am J Public Health Nations Health 1944;34:1274-1276.
233. Levitt LP, Mahoney DH, Casey HL, et al. Mumps in a general population: a sero-epidemiologic study. Am J Dis Child 1970;120:134-138.
234. Li M, Schmitt PT, Li Z, et al. Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles. J Virol 2009;83:7261-7272.
235. Liang Y, Ma S, Yang Z, et al. Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine 2008;26:4276-4283.
236. Lindsay JR, Davey PR, Ward PH. Inner ear pathology in deafness due to mumps. Ann Otol Rhinol Laryngol 1960;69:918-935.
237. Link H, Laurenzi MA, Fryden A. Viral antibodies in oligoclonal and polyclonal IgG synthesized within the central nervous system over the course of mumps meningitis. J Neuroimmunol 1981;1:287-298.
238. Litman N, Baum SG. Mumps Virus. In: Mandell GL, Bennett JE, Donlin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010:2201-2206.
239. Liu Y, Zhu J, Feng MG, et al. Six-helix bundle assembly and analysis of the central core of mumps virus fusion protein. Arch Biochem Biophys 2004;421:143-148.
240. Lohr JM, Oldstone MB. Detection of cytomegalovirus nucleic acid sequences in pancreas in type 2 diabetes. Lancet 1990;336:644-648.
241. London WT, Kent SG, Palmer AE, et al. Induction of congenital hydrocephalus with mumps virus in rhesus monkeys. J Infect Dis 1979;139:324-328.
242. Love A, Rydbeck R, Utter G, et al. Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis. J Virol 1986;58:220-222.
243. Lu LL, Puri M, Horvath CM, et al. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J Biol Chem 2008;283:14269-14276.
244. Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1-12.
245. Marin M, Quinlisk P, Shimabukuro T, et al. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine 2008;26:3601-3607.
246. Maris EP, Enders JF, Stokes J, et al. Immunity in mumps: IV. The correlation of the presence of complement-fixing antibodies in resistance to mumps in human beings. J Exp Med 1946;84:323-339.
247. Maruyama H, Tomizawa I. Reports on aseptic meningitis after MMR vaccination. Clin Virol 1994;22:77-82.
248. Maynard JE, Shramek G, Noble GR, et al. Use of attenuated live mumps virus vaccine during a "virgin soil" epidemic of mumps on St. Paul Island, Alaska. Am J Epidemiol 1970;92:301-306.
249. McAleer B, Rima B. Cloning and secreted expression of the extracellular domain of the mumps virus fusion protein in Pichia pastoris. Virus Genes 2000;20:127-133.
250. McCarthy M, Johnson RT. Morphological heterogeneity in relation to structural and functional properties of mumps virus. J Gen Virol 1980;48:395-399.
251. McCarthy M, Lazzarini RA. Intracellular nucleocapsid RNA of mumps virus. J Gen Virol 1982;58(Pt 1):205-209.
252. McFarland E. Immunizations for the immunocompromised child. Pediatr Ann 1999;28:487-496.
253. McGuiness AC, Gall EA. Mumps at army camps in 1943. War Med 1944;5:95-104.
254. McKenna M. Measles, mumps, and sensorineural hearing loss. Ann N Y Acad Sci 1997;830:291-298.
255. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases-United States, 2005. MMWR Morb Mortal Wkly Rep 2007;54:1-92.
256. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases-United States, 2006. MMWR Morb Mortal Wkly Rep 2008;55:1-92.
257. Merz DC, Server AC, Waxham MN, et al. Biosynthesis of mumps virus F glycoprotein: non-fusing strains efficiently cleave the F glycoprotein precursor. J Gen Virol 1983;64(Pt 7):1457-1467.
258. Meyer HM Jr, Johnson RT, Crawford IP, et al. Central nervous system syndromes of "vital" etiology. A study of 713 cases. Am J Med 1960;29:334-347.
259. Meyer MB. An epidemiologic study of mumps; its spread in schools and families. Am J Hyg 1962;75:259-281.
260. Meyer MB, Stifler WC, Joseph JM. Evaluation of mumps vaccine given after exposure to mumps, with special reference to the exposed adult. Pediatrics 1966;37:304-315.
261. Miller C, Miller E, Rowe K, et al. Surveillance of symptoms following MMR vaccine in children. Practitioner 1989;233:69-73.
262. Miller E, Andrews N, Stowe J, et al. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol 2007;165:704-709.
263. Miller E, Hill A, Morgan-Capner P, et al. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995;13:799-802.
264. Miller HG, Stanton JB, Gibbons JL. Para-infectious encephalomyelitis and related syndromes. A critical review of the neurological complications of certain specific fevers. Q J Med 1956;25:427-505.
265. Mizushima N, Murakami Y. Deafness following mumps: the possible pathogenesis and incidence of deafness. Auris Nasus Larynx 1986;13(Suppl 1):S55-S57.
266. Modlin JF, Orenstein WA, Brandling-Bennett AD. Current status of mumps in the United States. J Infect Dis 1975;132:106-109.
267. Montes M, Cilla G, Artieda J, et al. Mumps outbreak in vaccinated children in Gipuzkoa (Basque Country), Spain. Epidemiol Infect 2002;129:551-556.
268. Morgan HR, Enders JF. A hemolysin associated with the mumps virus. J Exp Med 1948;88:505-514.
269. Morishima T, Miyazu M, Ozaki T, et al. Local immunity in mumps meningitis. Am J Dis Child 1980;134:1060-1064.
270. Morrison TG. Structure and function of a paramyxovirus fusion protein. Biochim Biophys Acta 2003;1614:73-84.
271. Mortimer PP. Mumps prophlaxis in the light of a new test for antibody. Br Med J 1978;2:1523-1524.
272. Muhlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol 2004;4:215-219.
273. Nagai T, Nakayama T. Mumps vaccine virus genome is present in throat swabs obtained from uncomplicated healthy recipients. Vaccine 2001;19:1353-1355.
274. Nagai T, Okafuji T, Miyazaki C, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine 2007;25:2742-2747.
275. Nakayama T, Oka S, Komase K, et al. The relationship between the mumps vaccine strain and parotitis after vaccination. J Infect Dis 1992;165:186-187.
276. Nakayama T, Urano T, Osano M, et al. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response. Microbiol Immunol 1990;34:497-508.
277. Narita M, Matsuzono Y, Takekoshi Y, et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol 1998;5:799-803.
278. Naruse H, Nagai Y, Yoshida T, et al. The polypeptides of mumps virus and their synthesis in infected chick embryo cells. Virology 1981;112:119-130.
279. Ni J, Bowles NE, Kim YH, et al. Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent. Circulation 1997;95:133-139.
280. Nicolai-Scholten ME, Ziegelmaier R, Behrens F, et al. The enzyme-linked immunosorbent assay (ELISA) for determination of IgG and IgM antibodies after infection with mumps virus. Med Microbiol Immunol 1980;168:81-90.
281. Nicolle C, Conseil E. Essai de reproduction experimentale des oreillons chez le singe. Compt Rend Soc de Biol 1913;75:217.
282. Nishio M, Garcin D, Simonet V, et al. The carboxyl segment of the mumps virus V protein associates with Stat proteins in vitro via a tryptophan-rich motif. Virology 2002;300:92-99.
283. Nokes DJ, Wright J, Morgan-Capner P, et al. Serological study of the epidemiology of mumps virus infection in north-west England. Epidemiol Infect 1990;105:175-195.
284. Nussinovitch M, Brand N, Frydman M, et al. Transverse myelitis following mumps in children. Acta Paediatr 1992;81:183-184.
285. Odisseev H, Gacheva N. Vaccinoprophylaxis of mumps using mumps vaccine, strain Sofia 6, in Bulgaria. Vaccine 1994;12:1251-1254.
286. Ogata H, Oka K, Mitsudome A. Hydrocephalus due to acute aqueductal stenosis following mumps infection: report of a case and review of the literature. Brain Dev 1992;14:417-419.
287. Okamoto M, Shitara T, Nakayama M, et al. Sudden deafness accompanied by asymptomatic mumps. Acta Otolaryngol Suppl 1994;514:45-48.
288. Okazaki K, Tanabayashi K, Takeuchi K, et al. Molecular cloning and sequence analysis of the mumps virus gene encoding the L protein and the trailer sequence. Virology 1992;188:926-930.
289. Okuno Y, Asada T, Yamanishi K, et al. Studies on the use of mumps virus for treatment of human cancer. Biken J 1978;21:37-49.
290. Ong G, Goh KT, Ma S, et al. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect 2005;51:294-298.
291. Orvell C. Immunological properties of purified mumps virus glycoproteins. J Gen Virol 1978;41:517-526.
292. Orvell C. The reactions of monoclonal antibodies with structural proteins of mumps virus. J Immunol 1984;132:2622-2629.
293. Orvell C, Alsheikhly AR, Kalantari M, et al. Characterization of genotype-specific epitopes of the HN protein of mumps virus. J Gen Virol 1997;78(Pt 12):3187-3193.
294. Overman JR. Viremia in human mumps virus infections. Arch Intern Med 1958;102:354-356.
295. Overman JR, Peers JH, Kilham L. Pathology of mumps virus meningoencephalitis in mice and hamsters. Arch Pathol 1953;55:457-465.
296. Palihawadana P, Jayaratne IL, Wijemunige N. An outbreak of mumps in Dompe. Ceylon Med J 2007;52:35-36.
297. Paterson RG, Lamb RA. RNA editing by G-nucleotide insertion in mumps virus P-gene mRNA transcripts. J Virol 1990;64:4137-4145.
298. Pei Z, Bai Y, Schmitt AP. PIV5 M protein interaction with host protein angiomotin-like 1. Virology 2010;397:155-166.
299. Pei Z, Harrison MS, Schmitt AP. Parainfluenza virus 5 M protein interaction with host protein 14-3-3 negatively affects virus particle formation. J Virol 2011;85:2050-2059.
300. Peltola H, Davidkin I, Paunio M, et al. Mumps and rubella eliminated from Finland. JAMA 2000;284:2643-2647.
301. Peltola H, Jokinen S, Paunio M, et al. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008;8:796-803.
302. Penttinen K, Cantell K, Somer P, et al. Mumps vaccination in the Finnish defense forces. Am J Epidemiol 1968;88:234-244.
303. Permar SR, Klumpp SA, Mansfield KG, et al. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003;77:4396-4400.
304. Perry KR, Brown DW, Parry JV, et al. Detection of measles, mumps, and rubella antibodies in saliva using antibody capture radioimmunoassay. J Med Virol 1993;40:235-240.
305. Philip RN, Reinhard KP, Lachman DB. Observations on a mumps epidemic in a "virgin" population. Am J Hyg 1959;69:91-111.
306. Plans P. Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunization strategies. Med Decis Making 2010;30:438-443.
307. Plotkin SA, Rubin SA. Mumps Vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008:435-465.
308. Poch O, Blumberg BM, Bougueleret L, et al. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol 1990;71(Pt 5):1153-1162.
309. Poggio GP, Rodriguez C, Cisterna D, et al. Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases. J Clin Microbiol 2000;38:274-278.
310. Polgreen PM, Bohnett LC, Cavanaugh JE, et al. The duration of mumps virus shedding after the onset of symptoms. Clin Infect Dis 2008;46:1447-1449.
311. Ponka A, Pettersson T. The incidence and aetiology of central nervous system infections in Helsinki in 1980. Acta Neurol Scand 1982;66:529-535.
312. Pons C, Pelayo T, Pachon I, et al. Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy. Euro Surveill 2000;5:80-84.
313. Popow-Kraupp T, Kundi M, Ambrosch F, et al. A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children. J Med Virol 1986;18:69-79.
314. Porotto M, Murrell M, Greengard O, et al. Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites. J Virol 2004;78:13911-13919.
315. Pospisil L, Brycthova J. Adaptation of the mumps virus to the albino rat (Wistar). Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1956;165:1-8.
316. Postovit VA. [Epidemic parotitis in adults]. Voen Med Zh 1983:38-41.
317. Powell HM, Culbertson CG. Detection of mumps virus in mice sacrificed at different periods of time after injection. Proc Soc Exp Biol Med 1949;72:145-147.
318. Puri M, Lemon K, Duprex WP, et al. A point mutation, E95D, in the mumps virus V protein disengages STAT3 targeting from STAT1 targeting. J Virol 2009;83:6347-6356.
319. Rafiefard F, Johansson B, Tecle T, et al. Characterization of mumps virus strains with varying neurovirulence. Scand J Infect Dis 2005;37:330-337.
320. Ramachandran A, Horvath CM. Dissociation of paramyxovirus interferon evasion activities: universal and virus-specific requirements for conserved V protein amino acids in MDA5 interference. J Virol 2010;84:11152-11163.
321. Reed D, Brown G, Merrick R, et al. A mumps epidemic on St. George Island, Alaska. JAMA 1967;199:113-117.
322. Ritter BS. Mumps meningoencephalitis in children. J Pediatr 1958;52:424-433.
323. Roberts C, Porter-Jones G, Crocker J, et al. Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. Euro Surveill 2009;14(5):19109.
324. Rola-Pleszczynski M, Vincent MM, Hensen SA, et al. 51Chromium-release microassay technique for cell-mediated immunity to mumps virus: correlation with humoral and delayed-type skin hypersensitivity responses. J Infect Dis 1976;134:546-551.
325. Rota JS, Turner JC, Yost-Daljev MK, et al. Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J Med Virol 2009;81:1819-1825.
326. Rozina EE, Hilgenfeldt M. Comparative study on the neurovirulence of different vaccine strains of parotitis virus in monkeys. Acta Virol 1985;29:225-230.
327. Rozina EE, Kaptsova TI, Sharova OK, et al. Study of mumps virus invasiveness in monkeys. Acta Virol 1984;28:107-113.
328. Rubin SA, Afzal MA. Neurovirulence safety testing of mumps vaccines-historical perspective and current status. Vaccine 2011;29(16)2850-2855.
329. Rubin SA, Amexis G, Pletnikov M, et al. Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J Virol 2003;77:11616-11624.
330. Rubin SA, Mauldin J, Chumakov K, et al. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2005;24:2668.
331. Rubin SA, Pletnikov M, Carbone KM. Comparison of the neurovirulence of a vaccine and a wild-type mumps virus strain in the developing rat brain. J Virol 1998;72:8037-8042.
332. Rubin SA, Pletnikov M, Taffs R, et al. Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol 2000;74:5382-5384.
333. Rubin SA, Qi L, Audet SA, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis 2008;198:508-515.
334. Saika S, Kidokoro M, Ohkawa T, et al. Pathogenicity of mumps virus in the marmoset. J Med Virol 2002;66:115-122.
335. Saito H, Takahashi Y, Harata S, et al. Isolation and characterization of mumps virus strains in a mumps outbreak with a high incidence of aseptic meningitis. Microbiol Immunol 1996;40:271-275.
336. Santos CL, Ishida MA, Foster PG, et al. Detection of a new mumps virus genotype during parotitis epidemic of 2006-2007 in the State of Sao Paulo, Brazil. J Med Virol 2008;80:323-329.
337. Sanz JC, Mosquera MM, Echevarria JE, et al. Sensitivity and specificity of immunoglobulin G titer for the diagnosis of mumps virus in infected patients depending on vaccination status. APMIS 2006;114:788-794.
338. Sanz-Moreno JC, Limia-Sanchez A, Garcia-Comas L, et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine 2005;23:4921-4925.
339. Sauder CJ, Zhang CX, Link MA, et al. Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence. Vaccine 2009;27:5822-5829.
340. Sawada H, Yano S, Oka Y, et al. Transmission of Urabe mumps vaccine between siblings. Lancet 1993;342:371.
341. Schlegel M, Osterwalder JJ, Galeazzi RL, et al. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ 1999;319:352.
342. Schmitt PT, Ray G, Schmitt AP. The C-terminal End of PIV5 NP protein is important for virus-like particle production and M-NP protein interaction. J Virol 2010;84:12810-12823.
343. Schoub BD, Johnson S, McAnerney JM, et al. Measles, mumps and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990;9:263-267.
344. Schulz B, Michaelis D, Hildmann W, et al. Islet cell surface antibodies (ICSA) in subjects with a previous mumps infection-a prospective study over a 4 year period. Exp Clin Endocrinol 1987;90:62-70.
345. Schwarz NG, Bernard H, Melnic A, et al. Mumps outbreak in the Republic of Moldova, 2007-2008. Pediatr Infect Dis J 2010;29:703-706.
346. Scully C, Eckersall PD, Emond RT, et al. Serum alpha-amylase isozymes in mumps: estimation of salivary and pancreatic isozymes by isoelectric focusing. Clin Chim Acta 1981;113:281-291.
347. Server AC, Merz DC, Waxham MN, et al. Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun 1982;35:179-186.
348. Shah D, Vidal S, Link MA, et al. Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus. J Med Virol 2009;81:130-138.
349. Shulman A, Shohat B, Gillis D, et al. Mumps orchitis among soldiers: frequency, effect on sperm quality, and sperm antibodies. Fertil Steril 1992;57:1344-1346.
350. Sidhu MS, Menonna JP, Cook SD, et al. Canine distemper virus L gene: sequence and comparison with related viruses. Virology 1993;193:50-65.
351. Slater PE, Anis E, Leventhal A. The control of mumps in Israel. Eur J Epidemiol 1999;15:765-767.
352. Smith GA, Guessen R. Inner ear pathologic features following mumps infection. Arch Otolaryngol 1976;102:108-111.
353. Smorodintsev AA, Klyatchko NS. Live anti-mumps vaccine. I. Results of tests of the immunogenic properties of live vaccine when administered intradermally to susceptible children. Acta Virol 1958;2:137-144.
354. Somboonthum P, Yoshii H, Okamoto S, et al. Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Vaccine 2007;25:8741-8755.
355. Sosin DM, Cochi SL, Gunn RA, et al. Changing epidemiology of mumps and its impact on university campuses. Pediatrics 1989;84:779-784.
356. Spanaki A, Hajiioannou J, Varkarakis G, et al. Mumps epidemic among young British citizens on the island of Crete. Infection 2007;35:104-106.
357. St.Geme JW Jr, Peralta H, Van Pelt LF. Intrauterine infection of the rhesus monkey with mumps virus: abbreviated viral replication in the immature fetus as an explanation for split immunologic recognition after birth. J Infect Dis 1972;126:249-256.
358. Stratton KR, Howe CJ, Johnston RB. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994;271:1602-1605.
359. Sugg WC, Finger JA, Levine RH, et al. Field evaluation of live virus mumps vaccine. J Pediatr 1968;72:461-466.
360. Sullivan KM, Halpin TJ, Kim-Farley R, et al. Mumps disease and its health impact: an outbreak-based report. Pediatrics 1985;76:533-536.
361. Sun D, Luthra P, Li Z, et al. PLK1 down-regulates parainfluenza virus 5 gene expression. PLoS Pathog 2009;5:e1000525.
362. Sun M, Fuentes SM, Timani K, et al. Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses. J Virol 2008;82:105-114.
363. Takahashi Y, Teranishi A, Yamada Y, et al. A case of congenital mumps infection complicated with persistent pulmonary hypertension. Am J Perinatol 1998;15:409-412.
364. Takano T, Mekata Y, Yamano T, et al. Early ependymal changes in experimental hydrocephalus after mumps virus inoculation in hamsters. Acta Neuropathol 1993;85:521-525.
365. Takano T, Takikita S, Shimada M. Experimental mumps virus-induced hydrocephalus: viral neurotropism and neuronal maturity. Neuroreport 1999;10:2215-2221.
366. Takano T, Uno M, Yamano T, et al. Pathogenesis of cerebellar deformity in experimental Chiari type I malformation caused by mumps virus. Acta Neuropathol 1994;87:168-173.
367. Takeuchi K, Tanabayashi K, Hishiyama M, et al. The mumps virus SH protein is a membrane protein and not essential for virus growth. Virology 1996;225:156-162.
368. Takeuchi K, Tanabayashi K, Hishiyama M, et al. Variations of nucleotide sequences and transcription of the SH gene among mumps virus strains. Virology 1991;181:364-366.
369. Takikita S, Takano T, Narita T, et al. Neuronal apoptosis mediated by IL-1 beta expression in viral encephalitis caused by a neuroadapted strain of the mumps virus (Kilham Strain) in hamsters. Exp Neurol 2001;172:47-59.
370. Tanabayashi K, Takeuchi K, Hishiyama M, et al. Nucleotide sequence of the leader and nucleocapsid protein gene of mumps virus and epitope mapping with the in vitro expressed nucleocapsid protein. Virology 1990;177:124-130.
371. Tanabayashi K, Takeuchi K, Okazaki K, et al. Expression of mumps virus glycoproteins in mammalian cells from cloned cDNAs: both F and HN proteins are required for cell fusion. Virology 1992;187:801-804.
372. Taylor FB, Toreson WE. Primary mumps meningoencephalitis. Arch Intern Med 1963;112:114-119.
373. Tecle T, Johansson B, Jejcic A, et al. Characterization of three co-circulating genotypes of the small hydrophobic protein gene of mumps virus. J Gen Virol 1998;79(Pt 12):2929-2937.
374. Tecle T, Johansson B, Yun Z, et al. Antigenic and genetic characterization of the fusion (F) protein of mumps virus strains. Arch Virol 2000;145:1199-1210.
375. Tecle T, Mickiene A, Johansson B, et al. Molecular characterisation of two mumps virus genotypes circulating during an epidemic in Lithuania from 1998 to 2000. Arch Virol 2002;147:243-253.
376. Ternavasio-de la Vega HG, Boronat M, Ojeda A, et al. Mumps orchitis in the post-vaccine era (1967-2009): a single-center series of 67 patients and review of clinical outcome and trends. Medicine (Baltimore) 2010;89:96-116.
377. Tesovic G, Poljak M, Lunar MM, et al. Horizontal transmission of the Leningrad-Zagreb mumps vaccine strain: a report of three cases. Vaccine 2008;26:1922-1925.
378. Thompson JA, Glasgow LA. Intrauterine viral infection and the cell-mediated immune response. Neurol 1980;30:212-215.
379. Tillieux SL, Halsey WS, Sathe GM, et al. Comparative analysis of the complete nucleotide sequences of measles, mumps, and rubella strain genomes contained in Priorix-Tetra and ProQuad live attenuated combined vaccines. Vaccine 2009;27:2265-2273.
380. Timmons GD, Johnson KP. Aqueductal stenosis and hydrocephalus after mumps encephalitis. N Engl J Med 1970;283:1505-1507.
381. Toovey S, Jamieson A. Pancreatitis complicating adult immunisation with a combined mumps measles rubella vaccine. A case report and literature review. Travel Med Infect Dis 2003;1:189-192.
382. Tsurudome M, Yamada A, Hishiyama M, et al. Monoclonal antibodies against the glycoproteins of mumps virus: fusion inhibition by anti-HN monoclonal antibody. J Gen Virol 1986;67(Pt 10):2259-2265.
383. Tsurudome M, Yamada A, Hishiyama M, et al. Replication of mumps virus in mouse: transient replication in lung and potential of systemic infection. Arch Virol 1987;97:167-179.
384. Uchida K, Shinohara M, Shimada S, et al. Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real-time PCR. J Med Virol 2005;75:470-474.
385. Uchida K, Shinohara M, Shimada S, et al. Characterization of the F gene of contemporary mumps virus strains isolated in Japan. Microbiol Immunol 2003;47:167-172.
386. Ueda K, Miyazaki C, Hidaka Y, et al. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 1995;346:701-702.
387. Ukkonen P, Granstrom ML, Penttinen K. Mumps-specific immunoglobulin M and G antibodies in natural mumps infection as measured by enzyme-linked immunosorbent assay. J Med Virol 1981;8:131-142.
388. Ulane CM, Kentsis A, Cruz CD, et al. Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. J Virol 2005;79:10180-10189.
389. Ulane CM, Rodriguez JJ, Parisien JP, et al. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol 2003;77:6385-6393.
390. Unal M, Katircioglu S, Karatay MC, et al. Sudden total bilateral deafness due to asymptomatic mumps infection. Int J Pediatr Otorhinolaryngol 1998;45:167-169.
391. Usonis V, Bakasenas V, Chitour K, et al. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. Infection 1998;26:222-226.
392. Utz JP, Houk VN, Alling DW. Clinical and laboratory studies of mumps. IV. Viruria and abnormal renal function. N Engl J Med 1964;270:1283-1286.
393. Utz JP, Szwed CF. Mumps III. Comparison of methods for detection of viruria. Proc Soc Exp Biol Med 1962;110:841-844.
394. Utz JP, Szwed CF, Kasel JA. Clinical and laboratory studies of mumps. II. Detection and duration of excretion of virus in urine. Proc Soc Exp Biol Med 1958;99:259-261.
395. Vaheri A, Julkunen I, Koskiniemi ML. Chronic encephalomyelitis with specific increase in intrathecal mumps antibodies. Lancet 1982;2:685-688.
396. van Loon FPL, Holmes SJ, Sirotkin BI, et al. Mumps Surveillance-United States, 1988-1993. MMWR CDC Surveill Summ 1995;44:1-14.
397. Vandermeulen C, Roelants M, Vermoere M, et al. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004;22:2713-2716.
398. Vandvik B, Nilsen RE, Vartdal F, et al. Mumps meningitis: Specific and non-specific antibody responses in the central nervous system. Acta Neurol Scand 1982;65:468-487.
399. Vandvik B, Norrby E, Steen-Johnson J, et al. Mumps meningitis: prolonged pleocytosis and occurance of mumps virus-specific oligoclonal IgG in the cerebrospinal fluid. Eur Neurol 1978;17:13-22.
400. von Messling V, Milosevic D, Devaux P, et al. Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol 2004;78:7894-7903.
401. Vukic BT, Pavic I, Milotic I, et al. Aseptic meningitis after transmission of the Leningrad-Zagreb mumps vaccine from vaccinee to susceptible contact. Vaccine 2008;26:4879.
402. Vuori M, Lahikainen EA, Peltonen T. Perceptive deafness in connection with mumps. A study of 298 servicemen suffering from mumps. Acta Otolaryngol 1962;55:231-236.
403. Vuorinen T, Nikolakaros G, Simell O, et al. Mumps and Coxsackie B3 virus infection of human fetal pancreatic islet-like cell clusters. Pancreas 1992;7:460-464.
404. Waddell DJ, Wilbur JR, Merigan TC. Interferon production in human mumps infections. Proc Soc Exp Biol Med 1968;127:320-324.
405. Ward BJ, Boulianne N, Ratnam S, et al. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995;172:1591-1595.
406. Warrener L, Samuel D. Evaluation of a commercial assay for the detection of mumps specific IgM antibodies in oral fluid and serum specimens. J Clin Virol 2006;35:130-134.
407. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47:1-57.
408. Waxham MN, Server AC, Goodman HM, et al. Cloning and sequencing of the mumps virus fusion protein gene. Virology 1987;159:381-388.
409. Waxham MN, Wolinsky JS. A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1986;151:286-295.
410. Weibel RE, Buynak EB, McLean AA, et al. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 1975;56:380-387.
411. Weibel RE, Buynak EB, Stokes J Jr, et al. Persistence of immunity four years following Jeryl Lynn strain live mumps virus vaccine. Pediatrics 1970;45:821-826.
412. Weibel RE, Stokes J Jr, Buynak EB, et al. Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med 1967;276:245-251.
413. Weller TH, Craig JR. Isolation of mumps virus at autopsy. Am J Path 1949;25:1105-1115.
414. Weller TH, Enders JF. Production of hemagglutinin by mumps and influenza A viruses in suspended cell tissue cultures. Proc Soc Exp Biol Med 1948;69:124-128.
415. Westmore GA, Pickard BH, Stern H. Isolation of mumps virus from the inner ear after sudden deafness. Br Med J 1979;1:14-15.
416. Wharton M, Cochi SL, Hutcheson RH, et al. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988;158:1253-1260.
417. Wilfert CM. Mumps meningoencephalitis with low cerebrospinal-fluid glucose, prolonged pleocytosis and elevation of protein. N Engl J Med 1969;280:855-859.
418. Wilson RL, Fuentes SM, Wang P, et al. Function of small hydrophobic proteins of paramyxovirus. J Virol 2006;80:1700-1709.
419. Wolinsky JS, Baringer JR, Margolis G, et al. Ultrastructure of mumps virus replication in newborn hamster central nervous system. Lab Investig 1974;31:403-412.
420. Wolinsky JS, Klassen T, Baringer JR. Persistance of neuroadapted mumps virus in brains of newborn hamsters after intraperitoneal inoculation. J Infect Dis 1976;133:260-267.
421. Wolinsky JS, Stroop WG. Virulence and persistence of three prototype strains of mumps virus in newborn hamsters. Arch Virol 1978;57:355-359.
422. Wolinsky JS, Waxham MN, Server AC. Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol 1985;53:727-734.
423. Wollstein M. An experimental study of parotitis (mumps). J Exp Med 1916;23:353-378.
424. Wolontis S, Bjorvatin B. Mumps meningoencephalitis in Stockholm November 1964-July 1971. II. Isolation attemps from the cerebrospinal fluid in a hospitalized study group. Scand J Infect Dis 1973;5:261-271.
425. World Health Organization. Mumps virus vaccines: WHO position paper. Wkly Epidemiol Rec 2001;76:346-355.
426. World Health Organization. Mumps virus vaccines: WHO position paper. Wkly Epidemiol Rec 2007;82:49-60.
427. Woznik M, Rodner C, Lemon K, et al. The mumps virus small hydrophobic protein targets ataxin-1 ubiquitin-like interacting protein (ubiquilin 4). J Gen Virol 2010;91:2773-2781.
428. Wright KE, Dimock K, Brown EG. Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus. Virus Res 2000;67:49-57.
429. Yamada A, Takeuchi K, Tanabayashi K, et al. Sequence variation of the P gene among mumps virus strains. Virology 1989;172:374-376.
430. Yamauchi T, Wilson C, St.Geme JW Jr. Transmission of live, attenuated mumps virus to the human placenta. N Engl J Med 1974;290:710-712.
431. Yates PJ, Afzal MA, Minor PD. Antigenic and genetic variation of the HN protein of mumps virus strains. J Gen Virol 1996;77(Pt 10):2491-2497.
432. Yeo RP, Afzal MA, Forsey T, et al. Identification of a new mumps virus lineage by nucleotide sequence analysis of the SH gene of ten different strains. Arch Virol 1993;128:371-377.
433. Ylinen O, Jarniven PA. Parotitis during pregnancy. Acta Obstet Gynecol Scand 1953;32:121-132.
434. Yokosawa N, Kubota T, Fujii N. Poor induction of interferon-induced 2',5'-oligoadenylate synthetase (2-5 AS) in cells persistently infected with mumps virus is caused by decrease of STAT-1 alpha. Arch Virol 1998;143:1985-1992.
435. Yokosawa N, Yokota S, Kubota T, et al. C-terminal region of STAT-1alpha is not necessary for its ubiquitination and degradation caused by mumps virus V protein. J Virol 2002;76:12683-12690.
436. Yuzepchuk SA, Rozina EE, Kaptsova TI, et al. Morphological differences in the central nervous system and organs of monkeys inoculated intracerebrally with virulent and attenuated strains of mumps virus. Acta Virol 1975;19:305-310.
437. Zaitsev V, von Itzstein M, Groves D, et al. Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. J Virol 2004;78:3733-3741.
438. Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis 2004;189(Suppl 1):S131-S145.